权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Biomarkers of Kaposi sarcoma recrudescence in Zambia

赞比亚卡波西肉瘤复发的生物标志物

基本信息

批准号：
10454491
负责人：
Owen Ngalamika
金额：
$ 8.03万
依托单位：
UNIVERSITY OF ZAMBIA
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-09-16 至 2023-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10454491
关键词：
AIDS related cancer AIDS with Kaposi&apos s sarcoma Adult Africa South of the Sahara African Anti-Inflammatory Agents Antigens Biological Markers Bleomycin CD8-Positive T-Lymphocytes CXCL10 gene Cell Count Cell physiology Chemotherapy-Oncologic Procedure Clinical Cutaneous Detection Development Disease remission Doxorubicin Effector Cell Etiology Goals HIV HIV-1 Human Herpesvirus 8 Immune response Immunologics Immunotherapeutic agent In complete remission Individual Inflammatory Innate Immune Response Interferon Type II Interleukin-1 Interleukin-10 Interleukin-4 Interleukin-5 Interleukin-6 Intervention Kaposi Sarcoma Lesion Maintenance Therapy Malignant Neoplasms Manuscripts Measures Memory Outcome Pathogenesis Patient Selection Patients Peptides Peripheral Phenotype Plasma Poliomyelitis Population Predictive Value Preparation Prevalence Prospective Studies Recrudescences Recurrence Regimen Regulatory T-Lymphocyte Reporting T cell differentiation T cell response TNF gene Testing Transforming Growth Factor beta Update Vaccines Vincristine Viral Viral Load result Visit Woman Zambia anergy antiretroviral therapy biomarker identification chemokine chemotherapy clinical decision-making cohort cytokine design exhaustion experience follow-up high risk immune reconstitution improved individual response men neutralizing antibody novel pathogen prognostic value programmed cell death protein 1 prospective recruit response scale up senescence sociodemographics success tumor virology

项目摘要

ABSTRACT Kaposi's sarcoma (KS) remains a highly prevalent malignancy in sub-Saharan Africa. Antiretroviral therapy (ART) and associated immune reconstitution has been correlated with a dramatic decline in the prevalence of KS in the US HIV infected population, but the impact of ART on KS in sub-Saharan Africa is less clear. In Zambia, even with the scale up of ART, KS remains the second most common cancer among adult men. For women, it is the third most common. Furthermore, treatment with chemotherapy plus ART is associated with recurrence rates of up to 50 percent in those that have a complete response. The overall objective of this application is to identify markers of epidemic KS recurrence and/or sustained remission in individuals that have an initial complete regression of lesions upon chemotherapy. We hypothesize that individuals with complete regression of all the lesions after chemotherapy will have differences in immunological and viral factors that have prognostic value for predicting KS re-development and/or sustained remission. We will test our hypothesis by longitudinally characterizing innate, humoral, and cellular immune responses against KSHV and comparing individuals that experience recurrence to those who do not. The identification of these biomarkers of outcome after remission will enable the selection of patients that require a longer follow up period, those that require maintenance therapy, and those that require second line chemotherapy. From our proposed activities, we will improve the long-term outcomes of HIV+ individuals that have had KS before and hence at high risk of recurrence. This will ultimately inform efforts to better understand KS pathogenesis and develop novel interventional strategies.

摘要